Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA.

Mol Pharm. 2018 Jun 4;15(6):2133-2141. doi: 10.1021/acs.molpharmaceut.7b01133. Epub 2018 Apr 30.

PMID:
29684277
2.

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR.

Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.

3.

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS.

J Nucl Med. 2010 Aug;51(8):1293-300. doi: 10.2967/jnumed.110.076174. Epub 2010 Jul 21.

4.

Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.

Azhdarinia A, Voss J, Ghosh SC, Simien JA, Hernandez Vargas S, Cui J, Yu WA, Liu Q, Carmon KS.

Mol Pharm. 2018 Jun 4;15(6):2448-2454. doi: 10.1021/acs.molpharmaceut.8b00275. Epub 2018 May 8.

PMID:
29718672
5.

Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.

Rylova SN, Del Pozzo L, Klingeberg C, Tönnesmann R, Illert AL, Meyer PT, Maecke HR, Holland JP.

J Nucl Med. 2016 Jan;57(1):96-102. doi: 10.2967/jnumed.115.162735. Epub 2015 Oct 29.

6.

Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.

Nucl Med Biol. 2013 May;40(4):451-7. doi: 10.1016/j.nucmedbio.2013.01.007. Epub 2013 Feb 27.

7.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.

MAbs. 2014 Jul-Aug;6(4):1051-8. doi: 10.4161/mabs.29097. Epub 2014 May 7.

8.

Immuno-PET imaging of tumor endothelial marker 8 (TEM8).

Kuo F, Histed S, Xu B, Bhadrasetty V, Szajek LP, Williams MR, Wong K, Wu H, Lane K, Coble V, Vasalatiy O, Griffiths GL, Paik CH, Elbuluk O, Szot C, Chaudhary A, St Croix B, Choyke P, Jagoda EM.

Mol Pharm. 2014 Nov 3;11(11):3996-4006. doi: 10.1021/mp500056d. Epub 2014 Jul 11.

9.

ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.

Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC.

Cancer Biother Radiopharm. 2013 Sep;28(7):510-5. doi: 10.1089/cbr.2013.1487. Epub 2013 May 22.

10.

89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.

Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.

J Nucl Med. 2017 Sep;58(9):1386-1394. doi: 10.2967/jnumed.116.187310. Epub 2017 Mar 9.

11.

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. doi: 10.1007/s00259-008-0774-5. Epub 2008 May 20.

PMID:
18491091
12.

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.

Sharma SK, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, Sala E, Zeglis BM, Lewis JS.

J Nucl Med. 2016 May;57(5):771-6. doi: 10.2967/jnumed.115.167072. Epub 2016 Feb 2.

13.

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J.

J Nucl Med. 2011 Oct;52(10):1608-15. doi: 10.2967/jnumed.111.092098. Epub 2011 Sep 9.

14.

Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.

Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, Liu Z, Brechbiel MW, Hanai N, Nice EC, Catimel B, Burgess AW, Welt S, Ritter G, Old LJ, Scott AM.

Cancer Res. 2001 Jun 1;61(11):4474-82.

15.

Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.

Knowles SM, Zettlitz KA, Tavaré R, Rochefort MM, Salazar FB, Stout DB, Yazaki PJ, Reiter RE, Wu AM.

J Nucl Med. 2014 Mar;55(3):452-9. doi: 10.2967/jnumed.113.120873. Epub 2014 Feb 6.

16.

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.

Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS.

Mol Pharm. 2014 Nov 3;11(11):3965-73. doi: 10.1021/mp500164r. Epub 2014 May 6.

17.

ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.

Hernandez R, England CG, Yang Y, Valdovinos HF, Liu B, Wong HC, Barnhart TE, Cai W.

J Control Release. 2017 Oct 28;264:160-168. doi: 10.1016/j.jconrel.2017.08.029. Epub 2017 Aug 24.

18.

Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.

Natarajan A, Habte F, Gambhir SS.

Bioconjug Chem. 2012 Jun 20;23(6):1221-9. doi: 10.1021/bc300039r. Epub 2012 Jun 11.

19.

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS.

PLoS One. 2010 Jan 25;5(1):e8859. doi: 10.1371/journal.pone.0008859.

20.

Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET.

Adumeau P, Vivier D, Sharma SK, Wang J, Zhang T, Chen A, Agnew BJ, Zeglis BM.

Mol Pharm. 2018 Mar 5;15(3):892-898. doi: 10.1021/acs.molpharmaceut.7b00802. Epub 2018 Feb 2.

Supplemental Content

Support Center